Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors

HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ HybridizationAnalysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer

(2016) H. Evin Gulbahce et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

(2016) Sasagu Kurozumi et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

(2016) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study

(2016) Morgan Ballard et al.   MODERN PATHOLOGY

The topography of mutational processes in breast cancer genomes

(2016) Sandro Morganella et al.   Nature Communications

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

(2016) Anthony Ferrari et al.   Nature Communications

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis

(2016) Qian-Qian Xu et al.   Oncotarget

Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment

(2016) Niamh E. Buckley et al.   Scientific Reports

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer

(2015) Michalina Janiszewska et al.   NATURE GENETICS

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

(2015) Charlotte KY Ng et al.   GENOME BIOLOGY

HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer

(2014) Hee Jin Lee et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

(2013) L. Zabaglo et al.   ANNALS OF ONCOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

HER-2 intratumoral heterogeneity

(2013) Vincenzo Arena et al.   MODERN PATHOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance

(2012) Hyesil Seol et al.   MODERN PATHOLOGY

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

HeterogeneousHER2Gene Amplification

(2011) Alastair I. Bartlett et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know

(2010) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

(2010) S Guiu et al.   BRITISH JOURNAL OF CANCER

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

(2010) Luca Gianni et al.   LANCET

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY